Literature DB >> 26215964

Oncolytic Virus-Mediated Immunotherapy: A Combinatorial Approach for Cancer Treatment.

Sean E Lawler1, E Antonio Chiocca2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26215964     DOI： 10.1200/JCO.2015.62.5244

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  16 in total

1.  Stem cell-released oncolytic herpes simplex virus has therapeutic efficacy in brain metastatic melanomas.

Authors:  Wanlu Du; Ivan Seah; Oumaima Bougazzoul; GiHun Choi; Katrina Meeth; Marcus W Bosenberg; Hiroaki Wakimoto; David Fisher; Khalid Shah
Journal:  Proc Natl Acad Sci U S A       Date:  2017-07-14       Impact factor: 11.205

2.  Multi-modal Potentiation of Oncolytic Virotherapy by Vanadium Compounds.

Authors:  Mohammed Selman; Christopher Rousso; Anabel Bergeron; Hwan Hee Son; Ramya Krishnan; Nader A El-Sayes; Oliver Varette; Andrew Chen; Fabrice Le Boeuf; Fanny Tzelepis; John C Bell; Debbie C Crans; Jean-Simon Diallo
Journal:  Mol Ther       Date:  2017-10-24       Impact factor: 11.454

3.  Ovarian Cancer Cells Commonly Exhibit Defective STING Signaling Which Affects Sensitivity to Viral Oncolysis.

Authors:  Nina Marí Gual Pimenta de Queiroz; Tianli Xia; Hiroyasu Konno; Glen N Barber
Journal:  Mol Cancer Res       Date:  2018-12-26       Impact factor: 5.852

Review 4.  Dendritic cell-based immunotherapy.

Authors:  Rachel L Sabado; Sreekumar Balan; Nina Bhardwaj
Journal:  Cell Res       Date:  2016-12-27       Impact factor: 25.617

Review 5.  Surface modulatable nanocapsids for targeting and tracking toward nanotheranostic delivery.

Authors:  Marie Stark; R Holland Cheng
Journal:  Pharm Pat Anal       Date:  2016-09

Review 6.  Preclinical Mouse Models for Analysis of the Therapeutic Potential of Engineered Oncolytic Herpes Viruses.

Authors:  Maria-Carmela Speranza; Kazue Kasai; Sean E Lawler
Journal:  ILAR J       Date:  2016

Review 7.  Viral and other therapies for recurrent glioblastoma: is a 24-month durable response unusual?

Authors:  E Antonio Chiocca; Farshad Nassiri; Justin Wang; Pierpaolo Peruzzi; Gelareh Zadeh
Journal:  Neuro Oncol       Date:  2019-01-01       Impact factor: 12.300

8.  Noncanonical Cell Death Induction by Reassortant Reovirus.

Authors:  Roxana M Rodríguez Stewart; Vishnu Raghuram; Jameson T L Berry; Gaurav N Joshi; Bernardo A Mainou
Journal:  J Virol       Date:  2020-10-27       Impact factor: 5.103

9.  A classical PKA inhibitor increases the oncolytic effect of M1 virus via activation of exchange protein directly activated by cAMP 1.

Authors:  Kai Li; Jiankai Liang; Yuan Lin; Haipeng Zhang; Xiao Xiao; Yaqian Tan; Jing Cai; Wenbo Zhu; Fan Xing; Jun Hu; Guangmei Yan
Journal:  Oncotarget       Date:  2016-07-26

10.  Immunotherapeutic Potential of Oncolytic H-1 Parvovirus: Hints of Glioblastoma Microenvironment Conversion towards Immunogenicity.

Authors:  Assia L Angelova; Milena Barf; Karsten Geletneky; Andreas Unterberg; Jean Rommelaere
Journal:  Viruses       Date:  2017-12-15       Impact factor: 5.048
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.